Paradigm adds new oral combo IP to osteoarthritis drug stable with $500K pick-up
Paradigm Biopharmaceuticals (ASX:PAR) has acquired the exclusive global rights to develop @ and, of course, commercialise @ a novel oral combination of PPS and a COX-2 inhibitor designed to treat osteoarthritis and pains.Listen to the HotCopper podcast for in-depth discussions and insights on all...
The Watchlist
Previous Video
Next Video
3DA
AMAERO LTD
Hank Holland, Chairman & CEO
Hank Holland
Chairman & CEO
Previous Video
Next Video
SPONSORED BY The Market Online